Source link : https://www.newshealth.biz/health-news/fda-oks-mirdametinib-for-neurofibromatosis-type-1/
(MedPage Today) — The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1). Approval of the MEK inhibitor is specifically for patients who have symptomatic plexiform neurofibromas… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114182 Author : Publish date : 2025-02-11 22:31:40 Copyright for syndicated content belongs to the […]
Author : News Health
Publish date : 2025-02-11 22:31:40
Copyright for syndicated content belongs to the linked Source.